Free Trial
NASDAQ:GRTX

Galera Therapeutics 8/14/2024 Earnings Report

Galera Therapeutics logo
$0.02 0.00 (-1.67%)
As of 05/6/2025 11:31 AM Eastern

Galera Therapeutics EPS Results

Actual EPS
-$0.07
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Galera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galera Therapeutics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Galera Therapeutics' next earnings date is estimated for Monday, May 12, 2025, based on past reporting schedules.

Conference Call Resources

Galera Therapeutics Earnings Headlines

Galera Therapeutics extends agreement deadline
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Galera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galera Therapeutics and other key companies, straight to your email.

About Galera Therapeutics

Galera Therapeutics (NASDAQ:GRTX), a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

View Galera Therapeutics Profile

More Earnings Resources from MarketBeat